Our focus areas
We invest in scientific and technical excellence to develop and launch a pipeline of new products in a range of focus areas
R&D at GSK centres around science related to the immune system, the use of human genetics and advanced technologies. Our early-stage research is not constrained by therapy areas, with teams actively encouraged to follow the science. As projects progress, potential new medicines are aligned to the therapy area where data shows we can have the greatest impact to the largest number of patients.
Our work in Oncology is focused on maximising patient survival through transformational medicines. We are committed to helping those affected by cancer. We have significantly progressed our oncology pipeline organically and through external additions, with 17 programmes currently in clinical development.
We have a long-standing commitment to advancing the treatment, prevention and cure of HIV by developing innovative medicines that suppress or prevent the virus in new ways and help reduce the burden of treatment. Our HIV business is managed through ViiV Healthcare, a global company 100% dedicated to HIV that GSK controls as majority owner, with Pfizer and Shionogi also as shareholders. Its broad portfolio of 13 antiretroviral medicines offers a wide range of therapeutic options for people living with HIV.
Infectious diseases and global health
Our work to tackle infectious diseases includes bacterial, viral and parasitic infections. As part of our global health efforts, we are focusing on fighting the infectious diseases that impact children and adolescents in the developing world – in particular, malaria, tuberculosis (TB) and HIV/AIDS. Our world-leading centre at Tres Cantos has over 120 scientists working on potential new medicines for TB, malaria, Neglected Tropical Diseases like kinetoplastid diseases and causes of childhood diarrhoea.
We are focused on the biology of the immune system which plays a key role in causing a broad range of diseases. Our aim is to develop medicines that have the potential to alter the course of inflammatory diseases that are responsible for a significant health burden to patients and society.
We have led the way in developing modern innovative medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.
Since 2012, we have launched six respiratory medicines, giving us the broadest portfolio of once-daily, inhaled respiratory medicines in our industry.
Our investment in breakthrough vaccines technologies creates a real point of differentiation and will deliver further benefits in the future.